EN DE
Check 40,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Impact BioMedical, Inc. (IBO) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Impact BioMedical, Inc. stock $2.38, price $4.62, that is 48.5% below the price, quality 44 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

IB Impact BioMedical, Inc. logo Thin data Nov 11, 2026

Impact BioMedical, Inc.

IBO · US
Very expensive, weak quality

Our calculation puts a fair price 48% below what the stock costs today.

Costs just 0.4 times its yearly profit.
Quality 44/100
Mixed vs. peers (3/6)
Fair value $2.38 · Strongly overvalued
Weak Growth (revenue 3y −13.8 %/yr in USD)
Negative free cash flow
Narrow moat 42/100 · thin data
Thin data
Estimate⚠ Small free float

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$62.60 $2.68 Fair Value $2.38 Sep 2024 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 11, 2026.

How to read this chart

26‑month range $2.68 – $62.60 · fair‑value band $1.79 – $2.98 · the $4.62 price screens above the $2.38 fair value. As of Nov 11, 2026.

Follow Impact BioMedical in your weekly email

Every Wednesday you see whether Impact BioMedical is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Impact BioMedical Inc. discovers, develops, and commercializes products and technologies to address unmet needs in human healthcare and wellness for specialty biopharmaceuticals, antivirals, antimicrobials, consumer healthcare, and wellness products in the United States.

Show moreShow less

The company provides Linebacker, a platform of small molecule electrophilically enhanced polyphenol compounds with application in oncology, inflammatory disorders, and neurology; and Laetose technology that is derived from a unique combination of sugar and inositol, which can inhibit the inflammatory and metabolic response of sugar alone.

It also develops functional fragrance formulation, a suite of functional fragrances containing specialized botanical ingredients with application as an antimicrobial, and as an additive in insect repellents, detergents, lotions, shampoo, fabrics, and other substances.

In addition, the company develops Equivir/Equivir G technology, a novel blend of polyphenols, which have demonstrated antiviral effects for use as health supplements and medications. Further, it is developing 3F (functional fragrance formulation), a formulation of botanical ingredients.

Impact BioMedical Inc. was incorporated in 2018 and is based in Houston, Texas. Impact BioMedical Inc. operates as a subsidiary of DSS BioHealth Security, Inc

Stock analysis

Impact BioMedical, Inc. (IBO) currently trades at $4.62, while our estimate is $2.38, 48% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $1.79 (bear) to $2.98 (bull), the price of $4.62 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 44/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Impact BioMedical, Inc. reported revenue of $32.0K in FY2025 versus $50.0K in FY2021, a compound −10.6%/yr. Reported net income was −$11.8M in FY2025.

Key figures

Market cap $39.5M Micro · P/E ratio 0.4 · EPS (TTM) $11.11 · Return on equity 23.5% · Return on assets (EBIT) −8.9% (5-year average) · Operating margin −23,400% · Revenue (TTM) $35.0K · Revenue growth (YoY) −57.1%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).

What moves the price

The share trades about 53% below its 52-week high and 72% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −48%, IBO screens richer than that median.

Fair Value

Bear $1.79 Fair Value $2.38 Bull $2.98
Price $4.62 · Downside -48.5%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 44/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 2
Are margins and returns getting better?
Cashflow 25
Do the profits arrive as real cash?
Financial strength 66
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Price momentum 9
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 14
Distance to the 52-week high, does not count
New shares 100
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, no officer or director bought or sold shares on the open market.

  • SaleDSS, INC.10% owner906 shares at $1.86$1,687Sep 24, 2026
  • SaleTodd D MackoChief Financial Officer45,000 shares at $0.5614$25,264Mar 27, 2026
  • SaleJason GradyDirector50,000 shares at $0.6500$32,500Mar 23, 2026

Plus 9 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 10, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 14/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−98.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−13.8%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−6,370.0% (2021) → −13,343.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

IBO screens overvalued: fair value 48% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Impact BioMedical, Inc. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 3/6 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 44 · Above median
Fair Value upside −48.5% · Bottom 25%
Profitability
Return on equity (12 months) 23.5% · Top 25%
Return on assets −68.0% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −57.1% · Bottom 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/E (12 months) 0.4× · Cheapest 25%
P/B 3.13× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)94 · sector 0
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 20

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs IBO
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs IBO
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs IBO
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs IBO
argenx SE ARGX $971.55 $908.40 −7% vs IBO
CSL Limited CSL A$201.68 A$181.40 −10% vs IBO
Moderna, Inc MRNA $250.83 $158.70 −37% vs IBO
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs IBO
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs IBO
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs IBO

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Impact BioMedical, Inc.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Impact BioMedical, Inc. Fair Value". https://www.fairvalue-calculator.com/stock/IBO

Frequently asked questions

Is Impact BioMedical, Inc. (IBO) overvalued or undervalued?
As of Nov 11, 2026, our estimate of fair value is $2.38 versus a price of $4.62, about 48% lower (overvalued).
What is the fair value of IBO?
Our estimate for Impact BioMedical, Inc. is $2.38 (as of Nov 11, 2026), built from audited fundamentals. The current price: $4.62.
What is the quality score of IBO?
Impact BioMedical, Inc. has a Quality Score of 44/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Impact BioMedical, Inc. (IBO)?
Our calculated price target is the estimate of $2.38 (as of Nov 11, 2026). Cautious scenario $1.79, optimistic scenario $2.98. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Impact BioMedical, Inc. stock forecast for 2026?
Our estimate puts fair value at $2.38, about 48% lower versus a price of $4.62 (overvalued). Cautious scenario $1.79, optimistic scenario $2.98. The calculation is refreshed regularly with new filings.
What is the revenue of Impact BioMedical, Inc. (IBO)?
Impact BioMedical, Inc. reported trailing-twelve-month revenue of about $35.0K (latest available figure, as of Nov 11, 2026).
What is the intrinsic value of Impact BioMedical, Inc. (IBO)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Impact BioMedical, Inc. it is $2.38 per share (as of Nov 11, 2026), against a price of $4.62.
Is Impact BioMedical, Inc. stock overvalued or undervalued in 2026?
As of Nov 11, 2026, IBO trades above its calculated fair value: price $4.62, fair value $2.38, a gap of about −48% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of IBO?
No. The price is what the market pays today ($4.62); the fair value is what the company's own numbers justify ($2.38). For Impact BioMedical, Inc. the two are $2.24 per share apart. That gap is exactly why we show both numbers side by side.
How much is Impact BioMedical, Inc. worth?
The market values Impact BioMedical, Inc. at about $39.5M (market capitalisation, as of Nov 11, 2026). Per share that is $4.62; our models calculate a fair value of $2.38 per share.
What do the bullish and bearish scenarios say about IBO?
Our models span a range for Impact BioMedical, Inc.: cautious scenario $1.79, base $2.38, optimistic $2.98 per share (as of Nov 11, 2026, price $4.62). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of IBO?
Impact BioMedical, Inc. trades at a price-to-earnings ratio of 0.4 (as of Nov 11, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $2.38 is built from several models across several years. Other multiples: P/B 3.1.
How solid is the balance sheet of Impact BioMedical, Inc. (IBO)?
Balance-sheet figures for Impact BioMedical, Inc. (as of Nov 11, 2026): return on equity 23.5%. They feed the Quality Score of 44/100, which measures business quality independently of the share price.
How far is IBO from its 52-week high?
Impact BioMedical, Inc. trades at $4.62, about 53% below its 52-week high of $9.84 and 72% above the low of $2.68 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of $2.38 is for.
Which stocks are comparable to Impact BioMedical, Inc.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Impact BioMedical, Inc. stock attractive at the current price?
The data as of Nov 11, 2026: price $4.62, calculated fair value $2.38 (−48%), Quality Score 44/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Impact BioMedical, Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Impact BioMedical, Inc. (IBO)?
The closing price on Nov 10, 2026 was $4.62. Our estimate is $2.38, about 48% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Impact BioMedical, Inc. right now?
The price sits above even our optimistic bull case ($2.98). The favourable scenario is already priced in. Weak quality (44/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Impact BioMedical, Inc.

How large is the market capitalisation of Impact BioMedical, Inc. (IBO)?
The market capitalisation of Impact BioMedical, Inc. is $39.5M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Impact BioMedical, Inc. (IBO)?
Earnings per share at Impact BioMedical, Inc. are $11.11 (price ÷ EPS = P/E 0.4). Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Impact BioMedical, Inc. (IBO)?
The return on equity (ROE) of Impact BioMedical, Inc. is 23.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Impact BioMedical, Inc. (IBO)?
On an EBIT basis the return on assets of Impact BioMedical, Inc. is −8.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Impact BioMedical, Inc. (IBO)?
The operating margin of Impact BioMedical, Inc. is −23,400% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Impact BioMedical, Inc. (IBO)?
Revenue at Impact BioMedical, Inc. is growing −57.1% versus a year earlier (3y avg −13.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Impact BioMedical, Inc. (IBO) generate?
The free cash flow of Impact BioMedical, Inc. is −$1.9M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Impact BioMedical, Inc. (IBO) hold?
Impact BioMedical, Inc. holds more cash than debt, $3.0K net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Continue in the live analysis

Fair value and trend for 40,000+ stocks, watchlist, comparison and the diversification check.

Open the live analysis →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.